Skip to main content
SpringerLink
Log in

Giant Cell Arteritis

Epidemiology and Treatment

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Giant cell arteritis (GCA) was considered a rare disease 50 years ago; however, it is now known to be an important and significant cause of morbidity and mortality in elderly people. GCA is a generalised arteritis, although the aetiology and pathogenesis of this disorder are poorly understood. It is likely that there are environmental or genetic factors that significantly influence the risk for the disease in different populations.

Epidemiological studies have shown the highest incidence in Northern Europe and in Minnesota, US; which are populations of the same descent. Much lower incidence figures have been reported from more Southern regions of Europe and elsewhere. Possibly, the incidence of the disease is increasing as suggested by recent surveys.

Glucocorticosteroids are the drugs of choice in all clinical types of GCA. Most studies have been performed with prednisolone. There is no general agreement concerning the initial dosage, but 10 to 40 mg/day is commonly recommended. After a few months the majority of patients can be treated with a low maintenance dosage of prednisolone 5 to 7.5 mg/day. Because of the low dosage required, the frequency of corticosteroid-related adverse effects is relatively low. The median duration of treatment is about 5 years.

Nonsteroidal anti-inflammatory drugs, in contrast to corticosteroids, have no proven preventive effect on vascular complications of GCA, and cannot be recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alestig K, Barr J. Giant-cell arteritis. A biopsy study of polymyalgia rheumatica, including one case of Takayasu’s disease. Lancet 1: 1228–1230, 1963

    Article  PubMed  CAS  Google Scholar 

  • Amstrong RD, Panayi GS, Welsh KI. Polymyalgia rheumatica and rheumatoid arthritis. Similarity of HLA antigen frequencies. Correspondence. Arthritis and Rheumatism 27: 1438–1439, 1984

    Article  Google Scholar 

  • Andersson R, Malmvall BE, Bengtsson BÅ. Long-term corticosteroid treatment in giant cell arteritis. Acta Medica Scandinavica 220: 465–469, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Andersson R, Malmvall BE, Bengtsson BÅ. Acute phase reactants in the initial phase of giant cell arteritis. Acta Medica Scandinavica 220: 365–367, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Andersson R. Giant cell arteritis — immunology, long-term corticosteroid treatment and mortality. PhD Thesis, University of Göteborg, Göteborg, 1988

    Google Scholar 

  • Andersson R, Rundgren A, Rosengren K, Bengtsson BÅ, Malmvall BE, et al. Osteoporosis after long-term corticosteroid treatment of giant cell arteritis. Journal of Internal Medicine 227: 391–395, 1990

    Article  PubMed  CAS  Google Scholar 

  • Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. American Journal of Medicine 79: 309–315, 1985

    Article  PubMed  CAS  Google Scholar 

  • Barber S. Myalgic syndrome with constitutional effects. Annals of the Rheumatic Diseases 16: 230, 1967

    Article  Google Scholar 

  • Bacon PA, Doherty SM, Zuckerman AJ. Hepatitis B antibody in polymyalgia rheumatica. Lancet 2: 476–478, 1975

    Article  PubMed  CAS  Google Scholar 

  • Barrier J, Pion P, Massari R, Peltier P, Rojouan J, et al. Approche epidemiologique de la maladie de Horton dans la departement de Loire-Atlantique: 110 cas en 10 ans (1970–1979). Revue de Medicine Interne 1: 13–20,1982

    Article  Google Scholar 

  • Behn AR, Perra T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Annals of the Rheumatic Diseases 42: 374–378, 1983

    Article  PubMed  CAS  Google Scholar 

  • Bengtsson BÅ, Malmvall BE. An alternate-day corticosteroid regimen in maintenance therapy of giant arteritis. Acta Medica Scandinavica 209: 347–360, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Bengtsson BÅ, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis and Rheumatism 24: 899–904, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Bengtsson BÅ, Malmvall BE. Giant cell arteritis. Incidence of giant cell arteritis. Acta Medica Scandinavica 658 (Suppl.): 15–17, 1982

    Google Scholar 

  • Bengtsson BÅ. Epidemiology of giant cell arteritis. Bailliere’s Clinical Rheumatology 5: 379–385, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bielory L, Ogunkoya A, Frohman LP. Temporal arteritis in blacks. American Journal of Medicine 86: 707–708, 1989

    Article  PubMed  CAS  Google Scholar 

  • Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids. Journal of the American Medical Association 163: 821–827, 1957

    Article  PubMed  CAS  Google Scholar 

  • Boesen P, Sörensen SF. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica in a Danish County. A prospective investigation 1982–1985. Arthritis and Rheumatism 30: 294–299, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bogden DR, Glaser JS. Ischemic optic neuropathy. Brain 98: 689–708, 1975

    Article  Google Scholar 

  • Chuang TY, Hunder GG, Iistrup DM, Kurland LT. Polymyalgia rheumatica. A 10-year epidemiologic and clinical study. Annals of Internal Medicine 97: 672–680, 1982

    PubMed  CAS  Google Scholar 

  • Cid MC, Ercilla G, Vilaseca J, Sanmarti R, Villa1ta J, et al. Po1ymyalgia rheumatica — a syndrome associated with HLA-DR4 antigen. Arthritis and Rheumatism 31: 678–682, 1988

    Article  PubMed  CAS  Google Scholar 

  • Coomes EN, Ellis RM, Kay AG. A prospective study of 102 patients with the polymya1gia syndrome. Rheumatology and Rehabilitation 15: 270–276, 1976

    Article  PubMed  CAS  Google Scholar 

  • Dasgupta B, Gray J, Fernandes L, Olliff C. Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone. Annals of the Rheumatic Diseases 50: 942–945, 1991

    Article  PubMed  CAS  Google Scholar 

  • de Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatic a: a double-blind study. Annals of the Rheumatic Diseases 45: 136–138, 1986

    Article  PubMed  Google Scholar 

  • de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, et al. Treatment of giant cell arteritis with cyclophosphamide pulses. Correspondence. Journal ofInternal Medicine 232: 373–375, 1992

    Google Scholar 

  • Doury P, Pattin S, Eulry F, Thabaut A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis and Rheumatism 26: 689–690, 1983

    Article  PubMed  CAS  Google Scholar 

  • Elling H, Skinhoj P, Elling P. Hepatitis B virus and polymyalgia rheumatic a: a search for HBsAG, HBsAB, HBcAB, HBeAG, HBeAB. Annals of the Rheumatic Diseases 39: 511–513, 1980

    Article  PubMed  CAS  Google Scholar 

  • Esselinckx W, Doherthy SM, Dixon AStJ. Polymyalgia rheumatica. Abrupt and gradual withdrawal of prednisolone treatment, clinical and laboratory observations. Annals of the Rheumatic Diseases 36: 219–224, 1977

    Article  PubMed  CAS  Google Scholar 

  • Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Annals of Internal Medicine 77: 845–852, 1972

    PubMed  CAS  Google Scholar 

  • Fernandez-Herlihy L. Duration of corticosteroid therapy in giant cell arteritis. Journal of Rheumatology 7: 361–364, 1980

    PubMed  CAS  Google Scholar 

  • Fessel WJ. Polymyalgia rheumatica, temporal arteritis and contact with birds. Lancet 2: 1249–1250, 1969

    Article  PubMed  CAS  Google Scholar 

  • Franzen P, Suttinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study 1984–1988. Journal of Rheumatology 19: 273–276, 1992

    PubMed  CAS  Google Scholar 

  • Friedlander AH, Runyon C. Polymyalgia rheumatica and temporal arteritis. Oral Surgery, Oral Medicine and Oral Pathology 69: 317–321, 1990

    Article  CAS  Google Scholar 

  • Friedman G, Friedman B, Bombassat J. Epidemiology of temporal arteritis in Israel. Israel Journal of Medical Sciences 18: 241–244, 1982

    PubMed  CAS  Google Scholar 

  • Gilmour JR. Giant cell chronic arteritis. Journal of Pathology 53: 263–277, 1941

    Article  Google Scholar 

  • Gonzalez-Gay MA, Alonso MD, Aguero JJ, Bal M, Fernandez-Camblor B, et al. Temporal arteritis in a northwestern area of Spain: study of 57 biopsy-proven patients. Journal of Rheumatology 9 (2): 277–280, 1992

    Google Scholar 

  • Goodman BJ. Temporal arteritis. American Journal of Medicine 67: 839–862, 1979

    Article  PubMed  Google Scholar 

  • Granato JE, Abben RP, May WS. Familial association of giant cell arteritis: a case report and brief review. Achives of Internal Medicine 141: 115–117, 1981

    Article  CAS  Google Scholar 

  • Gray RES, Doherty SM, Galloway J, Coulton L, deBroe M, et al. A double-blind study of deflazacort and prednisolone in patients with chronic inflammatory disorders. Arthritis and Rheumatism 34 (3): 287–295, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hamilton CR, Shelley WM, Tumulty PA. Giant cell arteritis, including temporal arteritis and poly myalgia rheumatica. Medicine 50: 1, 1971

    Article  PubMed  Google Scholar 

  • Hamrin B. Poly myalgia arteritica. Acta Medica Scandinavica 192 (Suppl.): 86–99, 1972

    Google Scholar 

  • Hayreh SS. Ophthalmic features of giant cell arteritis. Bailliere’s Clinical Rheumatology 5 (3): 431–469, 1991

    Article  PubMed  CAS  Google Scholar 

  • Healey LA. Long-term follow-up of poly myalgia rheumatica: evidence for synovitis. Seminars in Arthritis and Rheumatism 13: 322–328, 1984

    Article  PubMed  CAS  Google Scholar 

  • Horton BT, Magath TB. Arteritis of the temporal vessels; report on seven cases. Proceedings of Star Meetings of Mayo Clinic 12: 548, 1937

    Google Scholar 

  • Hunder GG, Allen GL. The relationship between polymyalgia rheumatic a and temporal arteritis. Geriatrics 27: 134, 1973

    Google Scholar 

  • Hunder GG. More on polymyalgia rheumatica and giant cell arteritis. Western Journal of Medicine 141: 68–70, 1984

    PubMed  CAS  Google Scholar 

  • Hunder GG, Michet CJ. Giant cell arteritis and polymyalgia rheumatica. Clinics in Rheumatic Diseases 11: 471–483, 1985

    PubMed  CAS  Google Scholar 

  • Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, et al. The American College of Rheumatology 1990. Criteria for classification of giant cell arteritis. Arthritis and Rheumatism 33: 1122–1128, 1990

    Article  PubMed  CAS  Google Scholar 

  • Huston KA, Hunder GG. Temporal arteritis. A 25-year epidemiologic, clinical and pathologic study. Annals of Internal Medicine 88: 162–167, 1978

    PubMed  CAS  Google Scholar 

  • Hutchinson J. Diseases of the arteries. Archives of Surgery (London) 1: 323–329, 1890

    Google Scholar 

  • Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scottish Medical Journa1 24: 111–117, 1979

    CAS  Google Scholar 

  • Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Annals of the Rheumatic Diseases 40: 1–5, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kamide R, Ishikawa T, Aizawa H, Aoki I, Niimura M. A case of temporal arteritis successfully treated with recombinant interleukin-2. Journal of Dermatology 16: 487–491, 1989

    PubMed  CAS  Google Scholar 

  • Kemp A. Monocygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmologica (Copenhagen) 55: 183–190, 1977

    Article  CAS  Google Scholar 

  • Krall PL, Mazanec DJ, Wilke WS. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleveland Clinic Journal of Medicine 56: 253–257, 1989

    PubMed  CAS  Google Scholar 

  • Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Annals of the Rheumatic Diseases 48: 658–661, 1989

    Article  PubMed  CAS  Google Scholar 

  • Liang M, Greenberg H, Pincus T, Robinson WS. Hepatitis B antibody in polymyalgia rheumatica. Lancet 1: 43, 1976

    Article  PubMed  CAS  Google Scholar 

  • Love DC, Rapkin J, Lesser RG. Temporal arteritis in blacks. Annals of Internal Medicine 105: 387–389, 1986

    PubMed  CAS  Google Scholar 

  • Machado EBV, Michet CJ, Ballard DJ, Hunder GG, Beard CM, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota 1950–1985. Arthritis and Rheumatism 31: 745–749, 1988

    Article  PubMed  CAS  Google Scholar 

  • Meadows SP. Temporal or giant cell arteritis — ophthalmic aspects. In Smith JL (Ed.) Neuro-ophthalmology. Symposium of the University of Miami and the Bascom Palmer Eye Institute IV, pp. 148–157, St Louis, Mosby, 1968

    Google Scholar 

  • Nordborg E, Bengtsson BÅ. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. British Medical Journal 299: 549–550, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nordborg E, Bengtsson BÅ. Epidemiology of biopsy-proven giant cell arteritis (GCA). Journal of Internal Medicine 227: 233–236, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nordborg E, Bengtsson B, Nordborg C. Temporal artery morphology and morphometry in giant cell arteritis. Acta Pathologica et Microbiologica Immunologica Scandinavica 99: 1013–1023, 1991

    Article  CAS  Google Scholar 

  • Nordborg E, Hansson T, Jonson R, Szucs J, Bengtsson B. Bone minerai content of the third lumbar vertebra during 18–24 months of prednisolone treatment for giant cell arteritis. Clinical Rheumatology, in press, 1993

  • O’Brian JP. A concept of diffuse actinic arteritis: the role of actinic damage to elastin in age change and arteritis of the temporal artery and in polymyalgia rheumatica. British Journal of Dermatology 98: 1–13, 1978

    Article  Google Scholar 

  • Ornilla E, Swannell AJ, Dixon AStJ. Myalgia and birdkeeping. Lancet 2: 96, 1970

    Article  Google Scholar 

  • Ostberg G. On arteritis with special reference to polymyalgia arteritica. Acta Pathologica Microbiologica Scandinavica Section A 273 (Suppl.): 1–59, 1973

    Google Scholar 

  • Paulley JW. Anarthritic rheumatoid disease. Lancet 2: 946, 1956

    Article  Google Scholar 

  • Porsman VA. Proc II Congress European Editorial Scientia, Barcelona, p. 479, 1951

  • Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, et al. Corticosteroids and bone mass in asthma. Comparisons with rheumatoid arthritis and polymyalgiarheumatica. British Medical Journal 293: 1463–1466, 1986

    Article  PubMed  CAS  Google Scholar 

  • Richardson JE, Gladman DD, Fam A, Keystone EC. HLA DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis and Rheumatism 30: 1293–1297, 1987

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeldt SI, Kosmorsky GS, Klingeje TG, Burde RM, Cohn EM. Treatment of temporal arteritis with ocular involvement. American Journal of Medicine 80: 143–145, 1986

    Article  Google Scholar 

  • Salvarani C, Macchioni P, Zizzi F, Mantovani W, Rossi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in Northern Italy. Arthritis and Rheumatism 34 (3): 351–356, 1991

    Article  PubMed  CAS  Google Scholar 

  • Shick RM, Baggenstoss AH, Fuller BF, Polley HE Effects of cortisone and ACTH on periarteritis nodose and cranial arteritis. Staff meetings of the Mayo Clinic: 492–494, 1950

  • Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis. Report of a 10 year study of Shelby County, Tennessee. Arthritis and Rheumatism 25: 1214–1218, 1983

    Article  Google Scholar 

  • Soelberg-Sorensen P, Lorentzen I. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica. Acta Medica Scandinavica 201: 207–213, 1977

    Article  Google Scholar 

  • Spiera H, Davidson S. Long-term follow-up of polymyalgia rheumatica. Mount Sinai Journal of Medicine 45: 225–229, 1978

    PubMed  CAS  Google Scholar 

  • von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. Acta Medica Scandinavica 205: 429–435, 1979

    Article  Google Scholar 

  • Wilske KR, Healey LA. Polymyalgia rheumatica. A manifestation of systemic giant cell arteritis. Annals of Internal Medicine 66: 77–86, 1967

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Sahlgrenska Hospital, University of Göteborg, S-41345, Göteborg, Sweden

    Elisabeth Nordborg

  2. Department of Infectious Diseases, Östra Hospital, University of Göteborg, Göteborg, Sweden

    Rune Andersson

  3. Department of Internal Medicine, Sahlgrenska Hospital, University of Göteborg, Göteborg, Sweden

    Bengt-Åke Bengtsson

Authors
  1. Elisabeth Nordborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rune Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bengt-Åke Bengtsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nordborg, E., Andersson, R. & Bengtsson, BÅ. Giant Cell Arteritis. Drugs & Aging 4, 135–144 (1994). https://doi.org/10.2165/00002512-199404020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199404020-00006

Keywords

Search

Navigation